Ruffer LLP’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ruffer LLP’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,242	Closed	-$2.42M	–	211
2025 Q4	$2.42M	Buy	+14,242	New	+$2.18M	0.11%	119
2025 Q1	–	Sell	-58,767	Closed	-$7.24M	–	113
2024 Q4	$7.24M	Buy	+58,767	New	+$6.93M	0.26%	51
2024 Q2	–	Sell	-7,702	Closed	-$927K	–	58
2024 Q1	$927K	Hold	7,702	–	–	0.04%	52
2023 Q4	$947K	Hold	7,702	–	–	0.04%	60
2023 Q3	$1.01M	Hold	7,702	–	–	0.06%	58
2023 Q2	$955K	Hold	7,702	–	–	0.06%	57
2023 Q1	$1.13M	Hold	7,702	–	–	0.04%	70
2022 Q4	$1.23M	Hold	7,702	–	–	0.08%	61
2022 Q3	$1.07M	Hold	7,702	–	–	0.07%	72
2022 Q2	$1.2M	Hold	7,702	–	–	0.05%	69
2022 Q1	$1.2M	Hold	7,702	–	–	0.03%	77
2021 Q4	$1.01M	Hold	7,702	–	–	0.02%	76
2021 Q3	$996K	Hold	7,702	–	–	0.03%	68
2021 Q2	$1.37M	Buy	+7,702	New	+$1.33M	0.04%	61

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ruffer LLP's JAZZ Position: Q1 2026 in Review

Ruffer LLP sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 14,242 shares — an estimated $2.42M sold.

Ruffer LLP first reported a position in JAZZ in Q2 2021 and held it in 14 quarters. The position peaked at $7.24M in Q4 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Ruffer LLP reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Ruffer LLP sold 14,242 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.42M.
Ruffer LLP first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Ruffer LLP's Jazz Pharmaceuticals position peaked at $7.24M in Q4 2024.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Ruffer LLP's 13F filing for Q1 2026, filed 13 May 2026.